The risk for nonscarring hair loss (NSHL) is increased in association with glucagon-like peptide-1 receptor agonist (GLP-1 RA ...

GLP-1 therapy may lower CKD dementia risk and Alzheimer’s incidence in diabetic patients. Explore the latest evidence and clinical implications.

Combined GLP 1 receptor agonists and progestin therapy reduces endometrial cancer risk and hysterectomy rates in women with benign uterine conditions.

Tirzepatide (Zepbound, Mounjaro) is a dual-agonist GLP-1 medication. It works like a GLP-1 agonist, but also targets a ...

Although a growing body of evidence suggests a positive impact of GLP-1 receptor agonists in treating MS, questions of health ...

GLP-1 weight loss drugs have quickly moved from medical journals to household conversations, reshaping how Americans think ...

By Vijay Kumar Malesu Emerging evidence suggests that microbial metabolites not only regulate endogenous GLP-1 secretion but may also influence therapeutic response to GLP-1 receptor agonists, raising ...

This review examines how GLP-1 receptor agonists may influence neurodegenerative disease biology through metabolic, ...

A few clicks, a discounted vial, no prescription required. As demand surges for the new generation of weight-loss and diabetes drugs — particularly dual GIP and GLP-1 receptor agonists hailed as ...

Interest in the use and impacts of glucagon-like peptide-1 receptor agonists in rheumatology has exploded over the past year, a trend that appeared to crescendo at ACR Convergence 2025. There, ...

Bacteria in the gut may influence how GLP-1 receptor agonists work. This could help explain why patients do not respond ...